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A	 Fluoride‐derived	 Electrophilic	 Late‐Stage	 Fluorination	 Reagent	 for	 PET	
Imaging 
 
Late-stage fluorination with a reagent derived from [
18F]fluoride enables the synthesis of 
complex small molecules for use in position emission tomography (PET). 
 
Eunsung Lee#, Adam S. Kamlet#, David C. Powers, Constanze N. Neumann, Gregory B. 
Boursalian, Takeru Furuya, Daniel C. Choi, Jacob M. Hooker*, and Tobias Ritter* 
 
The unnatural isotope fluorine–18 (
18F) is used as a positron emitter in molecular 
imaging.  Currently, many potentially useful 
18F-labeled probe molecules are inaccessible 
for imaging, because no fluorination chemistry is available to make them.  Syntheses 
must be rapid on account of the 110-minute half-life of 
18F and benefit from using 
[
18F]fluoride due to practical access and suitable isotope enrichment.  But [
18F]fluoride 
chemistry has been limited to nucleophilic fluorination reactions.  Here we report the 
development of a palladium-based electrophilic fluorination reagent derived from 
fluoride and its application to the synthesis of aromatic 
18F-labeled molecules via late-
stage fluorination.  Late-stage fluorination enables the synthesis of conventionally 
unavailable positron emission tomography (PET) tracers for anticipated applications in 
pharmaceutical development as well as pre-clinical and clinical PET imaging. 
 
Positron emission tomography (PET) is a noninvasive imaging technology used to 
observe and probe biological processes in vivo (1,2).  While several positron-emitting 
isotopes can be used for PET imaging, fluorine–18 (
18F) is the most clinically relevant 
radioisotope (3,4).  For example, the radiotracer [
18F]fluorodeoxyglucose ([
18F]FDG) has 
revolutionized clinical diagnosis in oncology.  Despite the success of PET and decades of 
research, there remains a major deficiency in the ability to synthesize complex PET 
tracers; in fact, no general method is available to radiolabel structurally complex 
molecules with 
18F.  In organic molecules, fluorine atoms are typically attached by 
carbon–fluorine bonds (5), yet carbon–fluorine bond formation is challenging, especially 
in the presence of the variety of functional groups commonly found in structurally 2 
 
complex molecules (6).  For PET applications, chemical challenges are exacerbated by 
the short half-life of 
18F (110 minutes), which dictates that carbon–fluorine bond 
formation occur at a late-stage in the synthesis to avoid unproductive radioactive decay 
before injection in vivo. 
 
The unnatural isotope 
18F is generated using a cyclotron, either as nucleophilic 
[
18F]fluoride or as electrophilic [
18F]fluorine gas ([
18F]F2).  [
18F]Fluoride, formed from 
proton bombardment of oxygen–18-enriched water, is significantly easier to make and 
handle than [
18F]F2.  Moreover, [
18F]F2 gas is liberated from the cyclotron with [
19F]F2; 
19F is the natural, PET-inactive isotope of fluorine.  As a result, the 
18F/
19F ratio, 
quantified as specific activity, is substantially lower when [
18F]F2 is used than when 
[
18F]fluoride is used.  High specific activity is often critical to PET imaging.  If a 
biological target of a radiotracer is saturated with the non-positron-emitting 
19F-
isotopologue of the tracer, a meaningful PET image cannot be obtained.  Many biological 
targets cannot be visualized with PET tracers of low specific activity due to low 
concentration of the targets.  For example, imaging neurotransmitter receptors in the 
brain typically necessitates tracers of high specific activity (3). 
 
Research toward PET tracer development has focused on the use of [
18F]fluoride to make 
PET tracers in high specific activity.  Incorporation of 
18F still most commonly relies on 
simple nucleophilic substitution reactions, a class of reactions originally developed more 
than 100 years ago (7) and often not suitable to address modern challenges in imaging.  
Recent advances in nucleophilic fluorination (8–11) include a palladium-catalyzed 
fluorination reaction of aryl triflates with anhydrous cesium fluoride developed by the 
Buchwald group, in which carbonfluorine bond formation proceeds by reductive 
elimination from palladium(II) aryl fluoride complexes (12,13).  Challenges associated 
with the application of fluorination reactions to PET include the requirement of short 
reaction times as well as different reaction conditions for 
18F-chemistry compared to 
19F-
chemistry.  For example, extensive drying of fluoride is readily achieved for 
19F-
chemistry, but can be impractical for radiochemistry, which is typically executed on a 
nanomole scale.  The smaller ratio of fluorine to water, when transitioning from 
19F-3 
 
chemistry to 
18F-chemistry, can be problematic, because hydrated fluoride has diminished 
nucleophilicity.  As a consequence, even promising modern fluorination reactions 
developed for 
19F-chemistry are often not translated to radiochemistry. 
 
Electrophilic fluorination reactions allow access to a complementary set of molecules 
when compared to nucleophilic fluorination reactions (6).  Yet, all electrophilic 
18F-
fluorination reactions developed to date use electrophilic fluorination reagents that 
ultimately originate from [
18F]F2.  In 1997, Solin developed a method to generate [
18F]F2 
in higher specific activity than is common for [
18F]F2, by minimizing the amount of 
[
19F]F2 used (14).  By employing [
18F]F2 made via the Solin method, Gouverneur 
succeeded in synthesizing [
18F]F-TEDA, an electrophilic 
18F-fluorination reagent more 
useful and selective than [
18F]F2 (15).  However, nucleophilic [
18F]fluoride is currently 
the only practical and generally available source of fluorine to prepare high specific 
activity PET tracers (3).  If an electrophilic fluorination reagent were to be made from 
fluoride (16,17), without the need for F2, electrophilic fluorination could become a 
general and widely used method to prepare PET tracers that are presently inaccessible via 
conventional nucleophilic fluorination chemistry. 
 
Previously, we reported the fluorination of palladium aryl complexes with the 
electrophilic fluorination reagent F-TEDA (Fig. 1) (18).  F-TEDA can oxidize 
palladium(II) aryl complexes, which subsequently afford aryl fluorides by carbon–
fluorine reductive elimination from palladium(IV) aryl fluoride complexes (19,20).  
Replacement of F-TEDA by a fluorination reagent that mimics the function of F-TEDA, 
but is made from fluoride has the potential for use in the synthesis of high specific 
activity 
18F-radiotracers.  Here we report the design and synthesis of an organometallic 
complex made from fluoride (1 → 2, Fig. 1) that behaves as an electrophilic fluorination 
reagent, and the use of the reagent for the synthesis of 
18F-labeled small molecules via 
late-stage fluorination. 
 
Palladium complex 2 was envisioned to accomplish oxidative fluorine transfer by serving 
as an electrophile in SN2 reactions with nucleophilic attack occurring at the fluorine 4 
 
substituent.  The complexes 1 and 2  were designed based on the following five 
considerations (Fig. 2):  i) The palladium center in 1 carries three formal positive charges 
(counter charges to two triflate anions and one negatively charged borate ligand) and 
should therefore capture negatively charged fluoride from solution.  High fluorophilicity 
of the palladium complex 1 is required for radiochemistry applications due to the low 
effective concentration of fluoride in solution (roughly 10
-4 M).  ii) The palladium centers 
in 1 and 2 are in the oxidation state +IV (Pd(IV)), a high oxidation state for palladium.  
Late transition metals such as palladium, when in a high oxidation state, can function as 
an oxidant and transfer a ligand to a nucleophile, while being reduced in the process to a 
lower oxidation state (21).  The palladium in 2 can function as an electron acceptor, 
which rationalizes the reactivity of 2 as an oxidant.  iii) The supporting benzo[h]quinolyl 
and tetrapyrazole borate (Tp) ligands are multidentate ligands that were selected to impart 
stability on both 1 and 2 toward undesired reductive processes such as carbon–fluorine 
reductive elimination.  Reductive elimination from 2 would likely require dissociation of 
one ligand to form a pentacoordinate palladium complex (19,20), and multidentate 
ligands such as Tp are less likely to dissociate and hence reduce the rate of potential 
reductive elimination.  iv) An octahedral Pd(IV) complex was chosen to avoid undesired 
nucleophilic attack at the transition metal.  The palladium–fluorine bond is polarized 
toward fluorine, with partial negative charge on fluorine and positive charge on 
palladium.  Solely based on coulombic interactions, nucleophilic attack is expected at 
palladium rather than fluorine.  However, the orbitals available for nucleophilic attack on 
octahedral (t2g)
6 (eg)
0 Pd(IV) complexes, the dx2-y2 and dz2 orbitals, are high in energy, and 
nucleophilic attack on high energy orbitals is disfavored (22).  v) The multidentate 
supporting ligands in 2 feature aromatic substituents to prevent nucleophilic attack on the 
carbon and nitrogen atoms coordinated to palladium.  Complex 2 was devised to act as an 
electrophilic fluorination reagent through nucleophilic attack at the antibonding 
palladium–fluorine-based orbital (σ*Pd–F) at fluorine in an SN2 reaction.  In such a 
putative SN2 reaction, palladium would function as a leaving group, with concomitant 
reduction to the oxidation state +II (Pd(II)).  Nucleophilic attack would occur at the 
lowest unoccupied molecular orbital (LUMO) of 2.  The calculated LUMO of 2 (Fig. 
2B), shows that only the lobe on fluorine points into unoccupied space; no other LUMO 5 
 
lobe is available for nucleophilic attack because the aromatic ligands block the 
trajectories. 
 
Treatment of the palladium complex 1 with nucleophilic fluoride (KF) afforded the 
palladium fluoride complex 2 within five minutes in 90% yield (Fig. 2A).  The ability of 
2 to function as an electrophilic fluorination reagent was confirmed by fluorination of 
Pd(II) aryl complex 3 (Fig. 2C).  Fluorine transfer from 2 to 3 results in oxidation of 3 to 
form Pd(IV) aryl fluoride intermediate 5, assigned by 
1H and 
19F nuclear magnetic 
resonance (NMR).  Carbon–fluorine reductive elimination from reactive intermediate 5 
occurs at a rate comparable to oxidation of 3 with 2.  Oxidation of 3 with the electrophilic 
fluorination reagent F-TEDA afforded 5 at a faster rate than oxidation with 2, which 
allowed independent synthesis and identification of 5 (see Supporting Online Material, 
Fig. S2).  Reduction of palladium from Pd(IV) in oxidant 2 to Pd(II) was established by 
isolation of Pd(II) complex 4. 
 
Oxidative fluorine transfer from 2 to 3 could proceed by SN2 reaction as designed, with 
nucleophilic attack of the dz2-based orbital on palladium of 3 (Fig. S17) on the σ*Pd–F-
based orbital of the LUMO of 2, or via electron transfer (23,24) from 3 to 2 with 
interposed or subsequent fluorine transfer.  Current data cannot distinguish between these 
mechanisms.  In addition, other pathways that intercept intermediates such as 5 could 
potentially be used for carbon–fluorine bond formation.  Palladium complex 2 is both an 
oxidant and a fluoride donor.  The oxidation equivalents are inherent in the transition 
metal oxidation state, and the fluorine substituent is negatively polarized, because 
fluorine is the most electronegative element.  But oxidation of 3 with an external oxidant 
followed by reaction with an independent fluoride source could also provide 5.  In such a 
stepwise approach, potential side reactions of putative intermediates, such as undesired 
reductive elimination reactions, must be prevented.  Conceptually, several combinations 
of an oxidant and a fluoride source are conceivable for successful oxidative fluorination. 
 
The fluorination reagent 2 was subsequently evaluated for late-stage fluorination.   
Fluorination of the Pd(II) aryl complexes 8–11 with 2 afforded aryl fluorides 12–15 in 6 
 
67–93% yield (Fig. 3).  We propose that Pd(IV) fluoride complex 2 oxidizes the Pd(II) 
aryl complexes by fluorine transfer to form high-valent Pd(IV) aryl fluoride complexes, 
analogous to 5, from which carbon–fluorine reductive elimination can occur to form aryl 
fluoride products 12–15.  The aryl fluoride molecules shown in Figure 3 were selected 
based on their structure and exhibition of a variety of functional groups, akin to potential 
small-molecule PET tracers (25,26).  The molecules are electron-rich arenes, which 
would be challenging to prepare by conventional fluorination reactions with [
18F]fluoride. 
 
The transition from 
19F-chemistry to 
18F-chemistry is challenging because the 
concentration of the limiting reagent, fluoride, changes from mM to µM, and syntheses 
must be performed in the presence of ionizing radiation and under a time constraint due 
to the 110-minute half-life of 
18F.  Therefore, reaction chemistry applicable to 
18F-
chemistry must be robust and as simple as possible for broad applications in medical 
imaging.  Organometallic synthesis in a hospital setting would be impractical.  However, 
the palladium complexes discussed here can be prepared conveniently on scale, stored, 
and subsequently transported to imaging sites when needed.  The palladium(II) aryl 
complexes such as 8–11 can be purified by chromatography or recrystallization and can 
be stored and transported in air at ambient temperature.  Palladium complex 1 is stable at 
room temperature and can be manipulated briefly in air.  Palladium complex 2 is stable 
toward heat (no observed decomposition for 24 hours at 100 ºC), and water (no observed 
decomposition in 10% aqueous acetonitrile solution after 3 hours at 23 ºC).  Thermal 
stability and tolerance toward water are beneficial for practical PET applications, because 
reaction mixtures are often heated to increase reaction rates and [
18F]fluoride is made 
from oxygen–18-enriched water. 
 
The synthesis of 
18F-radiolabeled molecules using the presented fluoride-derived reagent 
is operationally simple.  Pd(IV) complex 1 reacts with conventionally prepared solutions 
of [
18F]fluoride in acetone and forms the 
18F-reagent [
18F]2 within ten minutes (Fig 4).  
Subsequent filtration over a polymer-supported resin and addition of the Pd(II) aryl 
complexes 9–11 afforded, upon heating for ten minutes, the 
18F-labeled aryl fluorides 
[
18F]13–15, respectively.  Azeotropic drying of aqueous [
18F]fluoride, the two-step 7 
 
reaction sequence (fluoride capture (1 → [
18F]2) followed by fluorine transfer (e.g. 9 → 
[
18F]13), and subsequent purification of the 
18F-labeled molecules by high-performance 
liquid chromatography (HPLC) results in an overall synthesis time of less than 60 
minutes.  Automated syntheses with up to 1 Ci of radioactivity have been accomplished.  
The efficiency of radiochemical synthesis is given in radiochemical yield, which is based 
on decay-corrected radioactivity rather than on mass of isolated material (4).  
Radiochemical yields (RCYs) as high as possible are desired, but RCYs as low as 5% can 
provide meaningful PET imaging (27).  The 
18F-fluorination method described here has 
afforded RCYs higher than 30%. 
 
Stoichiometric amounts of precious transition metals such as palladium are typically 
avoided in syntheses of health care products due to toxicity and cost considerations.   
However, such considerations are different for the synthesis of PET tracers due to the 
small amount that is required (28).  High-specific activity PET tracers are administered at 
a dose at least two orders of magnitude smaller than is common for pharmaceuticals 
because pharmacological effects are not sought (29), and purification is often 
straightforward due to the small amount of tracer to be purified.  For example, 
inductively coupled plasma mass spectrometry (ICP-MS) analysis of [
18F]13 (Fig. 4), 
purified by conventional HPLC technique (20 minutes), afforded material with 5 parts 
per billion (ppb) palladium residue, commensurate with international recommendations 
on the palladium impurity profile for samples injected into humans, which demand less 
than 1000 ppb palladium (30).  Similarly, the synthesis cost for the palladium complexes 
is small compared to the cost of 
18F-isotope infrastructure and the cost associated with 
clinical imaging (31). 
 
We have shown that the presented late-stage fluorination reaction can access 
18F-labeled 
functionalized molecules, which would be particularly difficult to prepare with 
conventional fluorination reactions.  The availability of a high specific activity 
fluorination reagent that functions as an electrophile may find applications in 
18F-
fluorination of pharmaceutical candidates for evaluation of their biodistribution to 8 
 
accelerate drug development, as well as in the development of previously unavailable 
18F-PET tracers for clinical care. 
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Fig 1. Electrophilic fluorination of palladium aryl complexes to afford aryl fluorides.  
Top: With the electrophilic fluorination reagent F-TEDA.  Bottom: With the Pd(IV) 
fluoride complex 2, made from fluoride (F⊝).  Ar, aryl; Me, methyl; Tf, 
trifluoromethanesulfonyl. 
 
Fig. 2. Reactivity and structure of 1 and 2.  (A) Nucleophilic fluoride capture by Pd(IV) 
complex 1 to form electrophilic fluorination reagent 2.  (B) X-ray structure of 2 (ORTEP 
drawing at 50% probability; hydrogen atoms and counteranion omitted for clarity), and 
calculated lowest unoccupied molecular orbital (LUMO) of 2.  (C) Fluorination of Pd(II) 
aryl complex 3 by reagent 2 to form Pd(IV) aryl fluoride complex 5, followed by C–F 
reductive elimination from 5.  Reductive elimination from reactive intermediate 5 to 6 
proceeds at 23 ºC; the highest yield of 6 (80%) was obtained upon heating 2 and 3 at 85 
ºC.  18-cr-6, 18-crown-6; 
iPr, isopropyl. 
 
Fig. 3. Synthesis and fluorination of palladium aryl complexes.  (A) Representative 
synthesis of a palladium aryl complex from palladium acetate complex 7.  (B) 
Fluorination of palladium aryl complexes 8–11 with electrophilic fluorination reagent 2.  
Ac, acetate; Bn, benzyl; Boc, tert-butoxycarbonyl; MOM, methyoxymethyl; DAM, di-(p-
anisyl)methyl. 
 
Fig. 4.  Late-stage fluorination to form 
18F-labeled aryl fluorides.  [
18F]Fluoride capture 
by Pd(IV) complex 1 to form electrophilic fluorination reagent [
18F]2 and subsequent 
fluorination of palladium aryl complexes 9–11.  Reported radiochemical yields (RCYs) 
are averaged over n experiments at a 500 µCi scale. N
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